The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upregulation of EPOR is a specific event for prostate carcinogenesis. An immunohistochemical analysis of EPOR was performed on 30 PCa, 50 BPH with/without inflammation lesions and 30 normal prostatic tissue samples. EPOR staining was quantitated and classified into normal expression and overexpression. Totally 16 high-grade PIN lesions were found in this study. Overexpression of EPOR was shown only in PCa and high-grade PIN. Statistical analysis demonstrated that higher median EPOR staining score of PCa and high-grade PIN in comparison with BPH (Po0.05) and higher median EPOR staining score of PCa compared with high-grade PIN (Po0.05). Our data demonstrate that upregulation of EPOR is not uncommon for PCa and upregulated EPOR in high-grade PIN suggests upregulation of EPOR is an early event for prostate carcinogenesis. The role of upregulated EPOR and possibly enhanced EPOR signaling in prostate carcinogenesis warrants further studying.
Introduction
Erythropoietin (EPO) secreted mainly by the kidney is a hematopoietic cytokine, which regulates erythropoiesis by binding to its specific transmembrane receptor, the erythropoietin receptor (EPOR) 1 . EPO was firstly isolated from an erythroleukemia cell line and fetal liver in 1990. 2 EPOR is a member of the type I cytokine receptor superfamily and characterized by the absence of intrinsic tyrosine kinase enzymatic activity. 3, 4 The binding of EPO to the extracellular domain of EPOR leads to a conformational change of receptor dimmers and subsequently activates Janus tyrosine kinase-2 signal pathway and phosphorylate tyrosine residues in the cytoplasmic domain of the erythropoietic receptor. The phosphorylated tyrosine residues serve as docking sites for various intracellular signaling proteins containing Src homology 2 domains including signal transducer-activator of transcription 5, mitogen-activated protein kinases, and phosphatidylinositol 3-kinase. These proteins can be activated by JAK-2-mediated tyrosine phosphorylation and then are involved in a complex network of EPOR signaling. [5] [6] [7] Traditionally, EPOR signaling is considered to be only responsible for erythropoiesis. But recent reports demonstrated EPOR expression in a variety of nonhemopoietic cells and organs, including the brain, cardiovascular tissues (endothelium, vascular smooth muscle, cardiomyocytes), the liver, gastrointestinal tissues, pancreatic islands, the kidney, the testis and the female reproductive organs. [8] [9] [10] [11] In addition, EPOR expression in the primary neoplasm and tumor cell lines such as melanoma, breast, renal, ovarian, gastric and uterine cancers as well as pediatric tumors was also reported. [12] [13] [14] [15] [16] [17] [18] In breast cancer, EPOR expression was shown only in cancerous tissues, but not in normal mammary tissues as detected by immunohistochemistry (IHC). 12 The newly appreciated biological effects of EPOR signaling, proangiogenesis and antiapoptosis, were reported to play an important role in carcinogenesis. 17, 19 Furthermore, two recent studies, the J&J's Breast Cancer Erythropoietin Trial (BEST) and the HoffmanLa Roche trial, on the therapeutic effects of human recombinant erythropoietin (rhEPO) have further shown that active EPOR signaling may promote tumor cell growth. The two trials had intended to confirm the beneficial effects of the new rhEPO drugs. 20, 21 However, in the Hoffman-La Roche trial rhEPO had adverse effects on patients' survival, while in BEST the rhEPO trial even had to be terminated permanently due to a higher mortality rate in the treatment group than in a control group. Although it is too hasty blaming rhEPO for the detrimental effects on cancer patients just from the two clinical trials, that had more or less design limitations, the role of EPOR signaling in carcinogenesis warrants further studying.
In the present study, we tested the hypothesis that the upregulation of EPOR is a specific event for prostate carcinogenesis using immunohistochemical assays of EPOR in normal prostatic tissues, benign prostatic hyperplasia (BPH) and prostate carcinoma (PCa) as well as their adjacent high-grade prostatic intraepithelial neoplasia (high-grade PIN).
Materials and methods

Patients and samples
Study protocols involving human materials were approved by the institutional ethic committee at Changhai Hospital. PCa tissue samples were from 30 patients with an age range of 60-77 years (average 70 years), who had undergone radical retropubic prostatectomy in our hospital. BPH tissue samples were from 50 patients with an age range from 62-79 years (average 72 years), who underwent transurethral resection of prostate. A total of 30 normal prostate tissue samples were obtained by autopsy from the patients aged from 20 to 30 years (average 24 years). Patients with PCa did not accept any treatment such as radiation, chemotherapy or hormonal therapy before the removal of the prostate. Tumors were scored with Gleason system. The prostate-specific antigen level at diagnosis ranged from 4.1 to 23.6 ng/ml. Some PCa samples had adjacent high-grade PIN lesions and some BPH samples contained inflammation lesions. Hematoxylin and eosin (H&E) stained slides of all cases were reviewed and the diagnosis was confirmed by two senior pathologists.
Immunohistochemical staining
Immunohistochemical assays were performed on formalin-fixed paraffin-embedded sections as described previously. 12 The primary antibodies used in immunohistochemical studies were rabbit polyclonal antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). First, 4 mm sections on glass slides were deparaffinized in Hemo-D and rehydrated in graded alcohols, followed by endogenous peroxidase block in 3% H 2 O 2 and antigen retrieval in boiling 10% citrate buffer. Then slides were incubated with the polyclonal antibody against EPOR (1:200 dilution) overnight at 41C and subsequently with horseradish peroxidase-labeled dextran polymer coupled to anti-rabbit antibody (DAKO Envision þ System HRP, DAKO Inc., Carpinteria, CA, USA) for 30 min at room temperature after three washes with Tris-buffered saline containing Tween-20 (TBST, pH 7.6, DAKO). Finally, slides were developed with diaminobenzidine for 10 min and counterstained with hematoxylin after washing three times with TBST. The specificity of staining was confirmed by processing sections from the same paraffin block with omission of the primary antibody (negative control). As a positive control, reactions with sections of breast cancer archived in the pathological department of our hospital were used. Cytoplasmic or membrane staining that was clearly distinguishable from the background was considered positive.
Semiquantitative analysis and interpretation of staining
At least 500 epithelial cells showing positive immunoreactivity within each area were evaluated in normal prostate, BPH, high-grade PIN and PCa. The percentage of cells with no staining (0) or weak (1), moderate (2) or intense staining (3) was analyzed by visual inspection under Â 100 magnification and a staining score was calculated using the formula: Weighted mean of stain intensity ¼ ( P intensity Â percentage of cells)/total percentage of cells. The scoring system took into account not only the staining intensity but also the percentage of the cells that exhibits EPOR staining. EPOR expression was graded semiquantitatively according to the results of staining score. In the present study EPOR staining was also classified into overexpression, which was defined as moderate or strong staining shown in any prostatic epithelium within benign or malignant tissues, and normal expression, which included weak or negative staining of EPOR. These analyses were performed using a Nikon E-400 microscope with computer-aided image analysis system, and digital images were captured using a digital camera (Nikon DU100, Tokyo, Japan) at Â 200 magnification. 22 Slides were blindly evaluated twice at different times by three investigators who were unaware of the pathologic characteristics, and the mean levels were used for the statistical analyses.
Statistics
Kruskal-Wallis test was used to compare differences in EPOR staining scores among groups. Linear regression was used to relate EPOR scores to Gleason scores in PCa. Computations were performed using SAS 8.1 software. A two-sided P-value of less than 0.05 was considered to be significant.
Results
PCa and BPH lesions were identified on H&E staining sections according to the morphological changes (Figure 1) . A total of 16 high-grade PIN lesions were found in 16 PCa samples and no PCa sample showed multiple high-grade PIN lesions.
EPOR expression was observed mainly in the glandular epithelium. A predominantly cytoplasmic pattern of staining for EPOR was presented and membrane immunoreactivity was also shown. EPOR staining level and median EPOR scores of different prostate tissues were shown in Table 1 . Overexpression of EPOR protein was shown in all the PCa samples and most high-grade PIN lesions, but not in normal prostate tissue or BPH with/without inflammation lesions. Furthermore, negative staining of EPOR was shown in all the normal prostate tissues. Representative photomicrographs for the expression of EPOR in PCa, high-grade PIN and BPH are shown in Figure 2 .
EPOR staining scores of PCa, high-grade PIN and BPH were further analyzed using the Kruskal-Wallis test 
Discussion
EPOR expression in human prostate was first reported by Feldman et al. 23 Subsequent studies from the same group further disclosed that the expression of EPOR in prostate was functional. 24 The authors found that all the normal or malignant cell lines analyzed exhibited EPO dose-dependent growth, owing to STAT5b phosphorylation activated by EPOR signaling.
Recently, Arcasoy et al. 25 investigated the expression of EPO and EPOR in human PCa. In clinical specimens of prostate cancer, they found abundant expression of EPOR protein in all primary tumors examined using immunohistochemistry. Moreover, the expression of EPO and EPOR in prostate cancer was more enhanced than that in benign prostate tissues. Furthermore, they also observed the expression of EPOR in well-characterized hormone-responsive (LNCaP) and hormone-refractory (PC-3) prostate cancer cell lines with RT-PCR, immunoprecipitation and immunoblotting. Our results support the findings of Arcasoy et al. that the expression of EPOR protein exists in PCa. However, we did not find an upregulation of EPOR in BPH with or without inflammation and normal prostate tissues. More importantly, we also found upregulated EPOR in high-grade PIN adjacent to the lesions of PCa, which has never been reported.
High-grade PIN is more important than low-grade PIN in clinic as a precursor lesion of PCa. The increasing amounts of high-grade PIN is always accompanied by a greater number of multifocal carcinomas 26 and both of them often occur in the same site of prostate, the peripheral zone. Moreover, high-grade PIN is associated with progressive abnormalities of phenotype and genotype, which are intermediate between normal prostatic epithelium and cancer, indicating that molecular mechanisms for high-grade PIN are possible mechanisms of prostatic carcinogenesis. In this study, the finding that upregulated EPOR appears in both PCa and adjacent high-grade PIN supports the notion that high-grade PIN has similar molecular alteration as PCa. Furthermore, more enhanced EPOR expression in PCa than adjacent high-grade PIN (higher EPOR score for PCa in comparison with high-grade PIN), the main precancerous lesion of PCa, suggests that up-regulation of EPOR may be an early event for prostate carcinogenesis.
There are several possible explanations for the upregulated EPOR in high-grade PIN and PCa. During normal development, EPOR expression in cells is transient, thus upregulated EPOR, the marker of delayed differentiation, corresponds to the incomplete differentiation status of high-grade PIN and PCa. Otherwise the upregulated EPOR in high-grade PIN and PCa may be induced by an oncogenic mechanism, 27 which has been reported to be involved in EPOR expression of tumors. More importantly, the upregulated EPOR may be a response to the hypoxia stress. Intratumoral hypoxia is common, and within high-grade PIN more oxygen consumption has been strongly suggested, 28, 29 which may result in relative hypoxic status. Hypoxia will stimulate HIF-1a, which can activate the down-stream 30 but the reason for such increase is unknown. It is likely that the upregulated EPOR with enhanced EPOR signaling is involved based on the following observations. It is well known that active-EPOR signaling can mediate the induction of bcl-2 and bcl-xL, an antiapoptotic gene of bcl-2 family. When cells are cultured in the absence of EPO, bcl-2 and bcl-xL are downregulated and the cells will undergo apoptosis. 31 Thus, by repressing cellular apoptosis upregulated EPOR plays a very important role in the formation of highgrade PIN and its progression to PCa.
Conclusions
Our data demonstrate that upregulation of EPOR is not uncommon for PCa. Furthermore, the upregulated EPOR in high-grade PIN suggests that EPOR upregulation is an early event in prostate carcinogenesis. The role of upregulated EPOR and possibly enhanced EPOR signaling in prostate carcinogenesis warrant further studying. Upregulation of EPOR in prostate cancer and high-grade PIN T Zhou et al
